Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Change in Accured Expenses (2016 - 2025)

PAVmed has reported Change in Accured Expenses over the past 5 years, most recently at -$175000.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 127.6% year-over-year to -$175000.0; the TTM value through Dec 2025 reached -$38000.0, down 101.96%, while the annual FY2025 figure was -$38000.0, 87.5% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$175000.0 at PAVmed, down from -$116000.0 in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $2.6 million in Q4 2021 and troughed at -$1.6 million in Q1 2022.
  • A 5-year average of $265578.9 and a median of $154000.0 in 2024 define the central range for Change in Accured Expenses.
  • Biggest five-year swings in Change in Accured Expenses: surged 18066.67% in 2023 and later plummeted 255.84% in 2025.
  • Year by year, Change in Accured Expenses stood at $2.6 million in 2021, then crashed by 70.57% to $775000.0 in 2022, then surged by 31.48% to $1.0 million in 2023, then crashed by 37.78% to $634000.0 in 2024, then crashed by 127.6% to -$175000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for PAVM at -$175000.0 in Q4 2025, -$116000.0 in Q3 2025, and $493000.0 in Q2 2025.